FLAG-Ida-Venetoclax vs CLIA-venetoclax for relapsed and refractory AML during a fludarabine shortage: A single center experience
Jose Tinajero(City Of Hope National Medical Center), Karamjeet Sandhu, Brian Ball(City Of Hope National Medical Center), Amandeep Salhotra(City of Hope), Paul Koller(City of Hope), Haris Ali(City of Hope), Hoda Pourhassan(City Of Hope National Medical Center), Salman Otoukesh(City Of Hope National Medical Center), Idoroenyi Amanam(City Of Hope National Medical Center), Brian Lee(City Of Hope National Medical Center), Amanda Blackmon(City Of Hope National Medical Center), Hoim Kim(City Of Hope National Medical Center), Dat Ngo(City Of Hope National Medical Center)
Cited by 0
Related Papers
BAFF-driven B cell hyperplasia underlies lung disease in common variable immunodeficiency
|JCI Insight|2019|87
Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease
|Biology of Blood and Marrow Transplantation|2018|84
Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents
|Blood Advances|2019|84
Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients
|Transplantation and Cellular Therapy|2021|78
Treatment of allosensitized patients receiving allogeneic transplantation
|Blood Advances|2021|66